Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis.

Liu Y, Hou W, Xie L, Yu X, Xie Y

Open source

DOI
10.1177/10849785261458478
Published
2026 Sep 17
Container
Cancer biotherapy & radiopharmaceuticals
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/10849785261458478,
  title = {Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis.},
  author = {Liu Y and Hou W and Xie L and Yu X and Xie Y},
  year = {2026},
  journal = {Cancer biotherapy \& radiopharmaceuticals},
  doi = {10.1177/10849785261458478},
  url = {https://doi.org/10.1177/10849785261458478}
}

RIS

TY  - JOUR
TI  - Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis.
AU  - Liu Y
AU  - Hou W
AU  - Xie L
AU  - Yu X
AU  - Xie Y
PY  - 2026
JO  - Cancer biotherapy & radiopharmaceuticals
DO  - 10.1177/10849785261458478
UR  - https://doi.org/10.1177/10849785261458478
ER  - 

APA

Y, L., W, H., L, X., X, Y., & Y, X. (2026). Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis.. Cancer biotherapy & radiopharmaceuticals. https://doi.org/10.1177/10849785261458478

Source records